{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:41:23Z","timestamp":1790912483903,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"52","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.vaccine.2017.11.013","type":"journal-article","created":{"date-parts":[[2017,11,23]],"date-time":"2017-11-23T04:46:24Z","timestamp":1511412384000},"page":"7231-7239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"title":["Herpes zoster vaccine live: A 10\u202fyear review of post-marketing safety experience"],"prefix":"10.1016","volume":"35","author":[{"given":"English D.","family":"Willis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Popmihajlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Saddier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula W.","family":"Annunziato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal A.","family":"Halsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne A.","family":"Gershon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.11.013_b0005","unstructured":"U.S. Food and Drug Administration. Approved Products: Zostavax. <http:\/\/wwwfdagov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm132831pdf> 2016. [Accessed 23 March 2017]."},{"key":"10.1016\/j.vaccine.2017.11.013_b0010","unstructured":"European Medicines Agency. Summary of Product Characterstics: Zostavax. <http:\/\/wwwemaeuropaeu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000674\/WC500053462pdf> 2016. [Accessed 23 March 2017]."},{"key":"10.1016\/j.vaccine.2017.11.013_b0015","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.11.013_b0020","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.11.013_b0025","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/cid\/cis638","article-title":"Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy","volume":"55","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.11.013_b0030","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.11.013_b0035","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/jama.2010.1983","article-title":"Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease","volume":"305","author":"Tseng","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.11.013_b0040","doi-asserted-by":"crossref","first-page":"e1001420","DOI":"10.1371\/journal.pmed.1001420","article-title":"Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study","volume":"10","author":"Langan","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2017.11.013_b0045","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1080\/21645515.2015.1016681","article-title":"Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status","volume":"11","author":"Marin","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.11.013_b0050","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/cid\/civ930","article-title":"Effectiveness of herpes zoster vaccine in patients 60 years and older with end-stage renal disease","volume":"62","author":"Tseng","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.11.013_b0055","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-152-9-201005040-00004","article-title":"Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial","volume":"152","author":"Simberkoff","year":"2010","journal-title":"Ann Int Med"},{"key":"10.1016\/j.vaccine.2017.11.013_b0060","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.4161\/hv.7.11.17982","article-title":"Safety and tolerability of zoster vaccine in adults >\/=60 years old","volume":"7","author":"Murray","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2017.11.013_b0065","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1016\/j.vaccine.2015.04.090","article-title":"Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic\/maintenance corticosteroids","volume":"33","author":"Russell","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.013_b0070","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1016\/j.vaccine.2010.04.003","article-title":"Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster","volume":"28","author":"Mills","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.013_b0075","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.vaccine.2006.11.011","article-title":"Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults","volume":"25","author":"Macaladad","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.013_b0080","unstructured":"Benson CHL, Andersen J, Jiang J, Bozzolo D, Annunziato P, Read S, et al. Zostavax is generally safe and immunogenic in HIV+ adults virologically suppressed on ART: results of a phase 2, randomized, double-blind, placebo-controlled trial CROI; 2012. Abstract #96."},{"key":"10.1016\/j.vaccine.2017.11.013_b0085","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/j.1532-5415.2007.01397.x","article-title":"Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older","volume":"55","author":"Kerzner","year":"2007","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.vaccine.2017.11.013_b0090","doi-asserted-by":"crossref","first-page":"894","DOI":"10.4161\/hv.6.11.12852","article-title":"Concomitant administration of zoster and pneumococcal vaccines in adults >\/=60 years old","volume":"6","author":"MacIntyre","year":"2010","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2017.11.013_b0095","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1128\/CVI.00310-07","article-title":"A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax","volume":"15","author":"Gilderman","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.11.013_b0100","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.vaccine.2006.10.027","article-title":"Safety and tolerability of a high-potency zoster vaccine in adults >\/= 50 or years of age","volume":"25","author":"Tyring","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.013_b0105","doi-asserted-by":"crossref","first-page":"6636","DOI":"10.1016\/j.vaccine.2012.08.070","article-title":"Safety of Zostavax\u2013a cohort study in a managed care organization","volume":"30","author":"Baxter","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.013_b0110","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1542\/peds.99.6.765","article-title":"The Vaccine Safety Datalink Team. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States","volume":"99","author":"Chen","year":"1997","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2017.11.013_b0115","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1365-2796.2011.02474.x","article-title":"Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study","volume":"271","author":"Tseng","year":"2012","journal-title":"J Int Med"},{"key":"10.1016\/j.vaccine.2017.11.013_b0120","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. E2D post-approval safety data management: definitions and standards for expedited reporting. <http:\/\/wwwichorg\/products\/guidelines\/efficacy\/efficacy-single\/article\/post-approval-safety-data-management-definitions-and-standards-for-expedited-reportinghtml> 2016. [Accessed 2 November 2016]."},{"key":"10.1016\/j.vaccine.2017.11.013_b0125","unstructured":"U.S. Food and Drug Administration. The FDA safety information and adverse event reporting program. <http:\/\/wwwfdagov\/Safety\/MedWatch\/HowToReport\/ucm053087htm> 2016. [Accessed 2 November 2016]."},{"key":"10.1016\/j.vaccine.2017.11.013_b0130","unstructured":"U.S. Food and Drug Administration. Draft guidance for industry: postmarketing safety reporting for human drug and biological products including vaccines. <http:\/\/wwwfdagov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Vaccines\/ucm074850htm> 2016. [Accessed 2 November 2016]."},{"key":"10.1016\/j.vaccine.2017.11.013_b0135","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/JVI.66.2.1016-1020.1992","article-title":"Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates","volume":"66","author":"LaRussa","year":"1992","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.11.013_b0140","unstructured":"Gershon ATM, Sewar J. Live attenuated varicella vaccine Vaccines. In: Plotkin S, Orenstein W, Offit P, editors. 6th ed. W.B. Saunders, Philadelphia; 2013."},{"key":"10.1016\/j.vaccine.2017.11.013_b0145","unstructured":"Vaccine Adverse Event Reporting System. <https:\/\/vaershhsgov\/index> 2017. [Accessed 10 March 2017]."},{"key":"10.1016\/j.vaccine.2017.11.013_b0150","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-212688","article-title":"Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient","volume":"2016","author":"Costa","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.vaccine.2017.11.013_b0155","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/cid\/ciu058","article-title":"Herpes zoster caused by vaccine-strain varicella zoster virus in an immunocompetent recipient of zoster vaccine","volume":"58","author":"Tseng","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.11.013_b0160","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/WNL.0000000000001109","article-title":"VZV encephalitis that developed in an immunized patient during fingolimod therapy","volume":"84","author":"Issa","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2017.11.013_b0165","first-page":"441","article-title":"Exacerbation of herpes zoster ophthalmicus (HZO) following zoster vaccine, live, attenuated Oka\/Merck: a case series","volume":"10\u201301","author":"Taylor","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2017.11.013_b0170","doi-asserted-by":"crossref","unstructured":"Kennedy DGS, Lillie R. Spontaneous reporting in the United States. In: Strom BL, editor. Pharmacoepidemiology, 3rd ed. Chicester, United Kingdom: Wiley; 2000. p. 151\u201374.","DOI":"10.1002\/0470842555.ch10"},{"key":"10.1016\/j.vaccine.2017.11.013_b0175","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1016\/j.vaccine.2012.04.005","article-title":"Algorithm to assess causality after individual adverse events following immunizations","volume":"30","author":"Halsey","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.013_b0180","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/infdis\/jit182","article-title":"Safety of zoster vaccine in elderly adults following documented herpes zoster","volume":"208","author":"Morrison","year":"2013","journal-title":"J Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2017.11.013_b0185","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1086\/522125","article-title":"The safety profile of varicella vaccine: a 10-year review","volume":"197","author":"Galea","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.11.013_b0190","unstructured":"Institute of Medicine of the National Academies. Adverse effects of vaccines: evidence and causality. In: Stratton K, Ford A, Rusch E, Clayton EW, editors. National Academies Press; Washington, DC; 2012."},{"key":"10.1016\/j.vaccine.2017.11.013_b0195","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1067\/mjd.2002.119091","article-title":"Visceral zoster as the presenting feature of disseminated herpes zoster","volume":"46","author":"Stratman","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.vaccine.2017.11.013_b0200","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.11.013_b0205","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/ard.2010.137216","article-title":"EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"70","author":"van Assen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2017.11.013_b0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.vaccine.2017.11.013_b0215","unstructured":"National Comprehensive Cancer Network, Inc., NCCN Guidelines for supportive care: survivorship. <https:\/\/wwwnccnorg\/professionals\/physician_gls\/f_guidelinesasp#supportive> 2013. [Accessed 17 October 2016]."},{"key":"10.1016\/j.vaccine.2017.11.013_b0220","unstructured":"Government of Canada Advisory Committee Statement\/National Advisory Committee on Immunization. Update on the use of herpes zoster vaccine. <http:\/\/publicationsgcca\/site\/eng\/9698776\/publicationhtml> 2014. [Accessed: 15 December 2015]."},{"key":"10.1016\/j.vaccine.2017.11.013_b0225","unstructured":"Public Health England. Shingles (herpes zoster). Green Book 2015; Chapter 28a. <https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/448815\/2904130_Green_Book_Chapter_28a_v1_0_0W_July2015.PDF> [Accessed: 28 July 2015]."},{"key":"10.1016\/j.vaccine.2017.11.013_b0230","unstructured":"Australian Government Department of Health. Zoster (herpes zoster). Australian Immunisation Handbook 2015; 10th Edition; Part 4.24. <http:\/\/www.immunise.health.gov.au\/internet\/immunise\/publishing.nsf\/Content\/Handbook10-home~handbookpart4~handbook-4-24#4--1> [Accessed: 1 October 2015]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17315724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17315724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T08:30:01Z","timestamp":1751013001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17315724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":46,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0264410X17315724"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.11.013","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Herpes zoster vaccine live: A 10\u202fyear review of post-marketing safety experience","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}